PAREXEL International Corp.  (PRXL) Trade Now »     Rate PRXL  -  Discuss PRXL  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

PRXL: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

PAREXEL International Corp. PRXL <> <> <>  <><><>< />< /><><><><><><><><><><><>...

62%		-49.86% in 528 days Analysts'  Recommendation: Buy       30 Days Ago: Buy     Analysts' Target: $49   <> <>
Analysts' Targets
Lehman Brothers	$27

PRXL PRXL

11%

-49.31% in 547 days I used a stock screener to find a list of good stocks then did some homework to come up with the pick. Continue reading »

From the Blogosphere

Healthcare in General and Contract Research Organizations in Particular Back in Good Graces

34%

We have seen a big rotation the past 2-3 sessions into healthcare; up and down the food chain. The thesis appears to be as details of Obama-care become more fine tuned there is less confusion and bad news is better than uncertainty in the stock market. One group that was mauled last year was the contract research organizations; as credit was shut off and healthcare firms under fire these stocks swooned. As I looked at some better performing groups not named "technology" or "commodities" I see a lot of relative strength here. I showcased 7 names from this group here about a year ago as we ... Continue reading »

Analyst upgrades, downgrades and initiations: AKAM, PFE, NYX, SCHW, SNDK

Filed under: Analyst reports, Analyst upgrades and downgrades, Pfizer (PFE), Charles Schwab Corp (SCHW), NYSE Euronext (NYX), Analyst initiations, Akamai Technologies (AKAM), SanDisk Corp (SNDK) Analyst upgrades: <> Merriman upgraded shares of Akamai (NASDAQ:AKAM) to Buy from Neutral as they believe consensus expectations are now realistic and already reflect macro headwinds. Merriman also thinks the company's cost reductions could generate upside to EPS estimates. <>JP Morgan upgraded Novo Nordisk (NYSE:NVO) to Overweight from Neutral on expectations the company's diabetes drug will gain ... Continue reading »

Analyst upgrades, downgrades and initiations: AKAM, PFE, NYX, SCHW, SNDK

Filed under: Analyst reports, Analyst upgrades and downgrades, Pfizer (PFE), Charles Schwab Corp (SCHW), NYSE Euronext (NYX), Analyst initiations, Akamai Technologies (AKAM), SanDisk Corp (SNDK) Analyst upgrades: <> Merriman upgraded shares of Akamai (NASDAQ:AKAM) to Buy from Neutral as they believe consensus expectations are now realistic and already reflect macro headwinds. Merriman also thinks the company's cost reductions could generate upside to EPS estimates. <>JP Morgan upgraded Novo Nordisk (NYSE:NVO) to Overweight from Neutral on expectations the company's diabetes drug will gain ... Continue reading »

Analyst upgrades, downgrades and initiations: MCD,NOK, DIS, DELL, AA,

Filed under: Analyst reports, Analyst upgrades and downgrades, Dell (DELL), McDonald's (MCD), Walt Disney (DIS), Nokia Corp. (NOK), Alcoa Inc (AA), AutoZone Inc (AZO), Gap Inc (GPS), Analyst initiations Analyst upgrades: <> UBS upgraded McDonald's (NYSE:MCD) to Buy from Neutral based on expectations the it can deliver on 2009 EPS expectations and potential for accelerating share gains. <>Bernstein upgraded Nokia (NYSE:NOK) to Outperform from Underperform on valuation following the company's profit warning. Merrill upgraded shares to Buy from Neutral to reflect valuation and Nokia's new pro... Continue reading »

Bookkeeping: Adding to Kendle International (KNDL) Ahead of Earnings

34%

For those who are newer readers, my general ethos is avoid stocks around earnings - while many get a kick out of the gambling associated with piling into stocks ahead of earnings hoping for the huge win - I find it a very risky game that has more bad outcomes than good. But the big moves in the small % of situations keep luring the gamblers... err investors... back to this (ahem) strategy. Kendle International (KNDL) reports on the 4th and I am going against my normal rules to add quite a bit of exposure ahead of earnings. We've outlined this week how the contract research organizations have... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.